Sirtex sees sales of SIR-Spheres ascend
Monday, 11 April, 2011
Sirtex (ASX:SRX) saw its stock bump by 2.5% to $5.45 in afternoon trading after announcing this morning that it has experienced its 27th consecutive quarter of dose sales growth of its anti-liver cancer treatment, SIR-Spheres.
Dose sales of the targeted radioactive treatment grew 20.7% for the quarter ending 31 March 2011 compared to the same quarter last year.
Year-to-date dose sales were up 18%, compared to 14.7% for the first three quarters of FY2010.
The fastest-growing market was Europe, up 23% compared to the same quarter last year, with US sales up 20% and Asia Pacific up 13%.
Revenue for FY2010 was $64.3 million, with a market cap of $304 million as of today.
The company posted a net profit of $3.6 million for the first half of FY2011, which is down 61% year-on-year due to the strong Australian dollar and increased costs, including higher prices from ANSTO of radiopharmaceuticals.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
